Phlexglobal Announces Availability of New eTMF AI
Phlexglobal has announced the general availability of PhlexTMF v21: an eTMF solution with artificial intelligence. Organizations can utilize PhlexTMF v21 to reduce TMF document misfiles and metadata errors—improving TMF quality, completeness, and timeliness.
PhlexTMF v21 immediately enables new as well as experienced document submitters to:
- Improve TMF quality and reduce inspection risk
- Increase the speed and accuracy of document submissions
- Focus on bringing TMF best practices around quality, completeness, and timeliness into the process earlier
Reference
Phlexglobal Announces Industry-First eTMF AI that Reduces Risk of Document Misfiles and Metadata Errors to Improve TMF Quality and Inspection-Readiness. (2023, March 20). Phlexglobal.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
